

Dirk J Van Veldhuisen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7952635/publications.pdf>

Version: 2024-02-01

341
papers

23,329
citations

9786

73
h-index

10734

138
g-index

348
all docs

348
docs citations

348
times ranked

22489
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	2.9	5
2	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 50-59.	3.3	6
3	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	3.8	10
4	The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction. <i>Heart and Vessels</i> , 2022, 37, 273-281.	1.2	8
5	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <sc>EMPHASIS</sc> and <sc>RALES</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 529-538.	7.1	7
6	Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after ST-segment Elevation Myocardial Infarction (GIPS-IV) trial. <i>American Heart Journal</i> , 2022, 243, 167-176.	2.7	12
7	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. <i>Europace</i> , 2022, 24, 910-920.	1.7	4
8	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	3.8	5
9	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTAT-CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	7.1	20
10	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	7.1	9
11	Natriuresis-guided therapy in acute heart failure: rationale and design of the <sc>Pragmatic Urinary Sodium-based treatment algorithm</sc> in <sc>Acute Heart Failure</sc> (<sc>PUSH-AHF</sc>) trial. <i>European Journal of Heart Failure</i> , 2022, 24, 385-392.	7.1	26
12	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	7.1	30
13	Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND. <i>Scientific Reports</i> , 2022, 12, 147.	3.3	21
14	Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: <sc>EAT</sc> your heart out!?. <i>European Journal of Heart Failure</i> , 2022, 24, 362-364.	7.1	0
15	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Oyerloc 112	13.7	112
16	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	4.1	115
17	Cardiovascular determinants of impaired placental function in women with cardiac dysfunction. <i>American Heart Journal</i> , 2022, 245, 126-135.	2.7	7
18	Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2022, 43, 1955-1969.	2.2	90

#	ARTICLE	IF	CITATIONS
19	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. <i>Journal of Internal Medicine</i> , 2022, 291, 713-731.	6.0	23
20	The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients. <i>ESC Heart Failure</i> , 2022, 9, 953-957.	3.1	9
21	Renal Compression in Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 175-183.	4.1	44
22	Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. <i>European Journal of Heart Failure</i> , 2022, 24, 526-528.	7.1	4
23	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	4.5	4
24	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
25	Sex differences in associations of comorbidities with incident cardiovascular disease: focus on absolute risk. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	2
26	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	7.1	15
27	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	3.3	10
28	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009238.	3.9	40
29	Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, , .	7.1	8
30	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	3.1	4
31	Decongestion, kidney injury and prognosis in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2022, 354, 29-37.	1.7	6
32	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	2.7	5
33	Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. <i>Journal of Clinical Medicine</i> , 2022, 11, 125.	2.4	45
34	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	7.3	7
35	A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?. <i>European Heart Journal</i> , 2022, 43, 2221-2223.	2.2	6
36	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1009-1019.	7.1	6

#	ARTICLE	IF	CITATIONS
37	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	7.1	8
38	Heart Failure and Pancreas Exocrine Insufficiency: Pathophysiological Mechanisms and Clinical Point of View. <i>Journal of Clinical Medicine</i> , 2022, 11, 4128.	2.4	6
39	Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 1193-1201.	3.3	2
40	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 648-656.	7.1	13
41	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	3.8	8
42	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 436-444.	7.1	20
43	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 68-78.	7.1	79
44	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 533-541.	1.7	11
45	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	7.1	19
46	Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 64-71.	1.2	1
47	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007684.	3.9	87
48	Relationship between body mass index, cardiovascular biomarkers and incident heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 396-402.	7.1	17
49	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.	7.1	12
50	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , 2021, 9, 201-211.	4.1	6
51	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1554-1563.	3.3	5
52	Epicardial fat in heart failure with reduced versus preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 835-838.	7.1	30
53	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	7.1	9
54	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	7.3	15

#	ARTICLE	IF	CITATIONS
55	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	7.1	70
56	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	7.1	26
57	The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases. <i>Europace</i> , 2021, 23, ii40-ii45.	1.7	23
58	Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1122-1130.	7.1	14
59	Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. <i>Europace</i> , 2021, 23, 1359-1368.	1.7	11
60	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	2.8	35
61	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	3.9	25
62	Sudden cardiac death in heart failure: more than meets the eye. <i>European Journal of Heart Failure</i> , 2021, 23, 1361-1363.	7.1	2
63	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	1.8	3
64	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 37</i>		
65	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	3.1	33
66	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1308-1320.	3.3	3
67	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. <i>American Journal of Cardiology</i> , 2021, 147, 70-79.	1.6	7
68	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008075.	3.9	3
69	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2458-2466.	3.1	13
70	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021, 23, 1170-1181.	7.1	11
71	Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid-range and preserved ejection fraction. <i>Clinical Cardiology</i> , 2021, 44, 987-993.	1.8	22
72	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1301-1313.	2.8	10

#	ARTICLE	IF	CITATIONS
73	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	7
74	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	7.1	11
75	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTAT-CHF</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	7.1	32
76	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	4.1	21
77	Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1421-1432.	2.8	21
78	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. <i>Heart Rhythm O2</i> , 2021, 3, 40-49.	1.7	0
79	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-CHF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	3.7	13
80	Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
81	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	3.3	28
82	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	7.1	28
83	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , 2020, 71, 62-69.	2.2	12
84	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	7.1	50
85	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	7.1	15
86	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	7.1	19
87	Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. <i>European Journal of Heart Failure</i> , 2020, 22, 251-263.	7.1	19
88	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
89	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	7.1	33
90	Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right. <i>International Journal of Cardiology</i> , 2020, 306, 152-157.	1.7	5

#	ARTICLE	IF	CITATIONS
91	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020, 38, 420-425.	0.5	12
92	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1415-1423.	7.1	84
93	Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. <i>Europace</i> , 2020, 22, 1619-1627.	1.7	22
94	Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens. <i>European Journal of Heart Failure</i> , 2020, 22, 455-457.	7.1	4
95	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	7.1	15
96	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	7.1	24
97	Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS). <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-8.	1.2	12
98	Reduced right ventricular function on cardiovascular magnetic resonance imaging is associated with uteroplacental impairment in tetralogy of Fallot. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 52.	3.3	4
99	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <sc>VIP&HF</sc> study. <i>European Journal of Heart Failure</i> , 2020, 22, 1923-1929.	7.1	25
100	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4047-4049.	2.2	7
101	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <sc>PARAGON&HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.	7.1	33
102	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.2	101
103	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
104	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	2.2	381
105	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 35, 953-963.	2.6	4
106	Surviving the first <sc>COVID</sc>-19 wave and learning lessons for the second. <i>European Journal of Heart Failure</i> , 2020, 22, 975-977.	7.1	12
107	Right-sided cardiac disease: no longer the "dark side of the heart". <i>European Journal of Heart Failure</i> , 2020, 22, 1226-1229.	7.1	1
108	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65

#	ARTICLE	IF	CITATIONS
109	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1158-1168.	3.0	10
110	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	4.1	14
111	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020, 7, 953-963.	3.1	9
112	Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 667-676.	4.1	45
113	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <i>BIOSTAT-CHF</i> and <i>ASIAN-CHF</i> registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	7.1	24
114	What should the C (congestive heart failure™) represent in the <i>CHA₂DS₂-VASc</i> score?. <i>European Journal of Heart Failure</i> , 2020, 22, 1294-1297.	7.1	10
115	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	4.1	25
116	Clinical importance of urinary sodium excretion in acute heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1438-1447.	7.1	55
117	Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation – Data from RACE 3. <i>American Heart Journal</i> , 2020, 226, 235-239.	2.7	8
118	Geographical differences in heart failure characteristics and treatment across Europe: results from the <i>BIOSTAT-CHF</i> study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	3.3	7
119	Trajectory of self-care behaviour in patients with heart failure: the impact on clinical outcomes and influencing factors. <i>European Journal of Cardiovascular Nursing</i> , 2020, 19, 421-432.	0.9	31
120	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 903-906.	7.1	3
121	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	7.1	28
122	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	3.3	20
123	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. <i>Cardiac Failure Review</i> , 2020, 6, e21.	3.0	2
124	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019, 108, 133-141.	3.3	6
125	Residual confounding in observational studies: new data from the old DIG trial. <i>European Heart Journal</i> , 2019, 40, 3342-3344.	2.2	7
126	Cancer and heart disease: associations and relations. <i>European Journal of Heart Failure</i> , 2019, 21, 1515-1525.	7.1	120

#	ARTICLE	IF	CITATIONS
127	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	4.1	77
128	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	4.1	22
129	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019, 7, 970-979.	4.1	26
130	Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. <i>Europace</i> , 2019, 21, 563-571.	1.7	19
131	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	13.7	159
132	Effect of Systolic Blood Pressure on Left Ventricular Structure and Function. <i>Hypertension</i> , 2019, 74, 826-832.	2.7	23
133	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019, 40, 3616-3625.	2.2	69
134	Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?. <i>European Journal of Heart Failure</i> , 2019, 21, 480-481.	7.1	0
135	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019, 40, 3593-3602.	2.2	69
136	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <i>Journal of Cardiac Failure</i> , 2019, 25, 654-665.	1.7	23
137	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 696.	6.1	43
138	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	7.1	172
139	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	3.9	23
140	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. <i>JAMA Cardiology</i> , 2019, 4, 515.	6.1	51
141	Sodium-glucose cotransporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>European Journal of Heart Failure</i> , 2019, 21, 862-873.	7.1	236
142	Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019, 114, 6-13.	2.6	4
143	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 732-743.	7.1	64
144	Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data. <i>Heart</i> , 2019, 105, 873-880.	2.9	24

#	ARTICLE	IF	CITATIONS
145	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. <i>European Heart Journal</i> , 2019, 40, 1287-1293.	2.2	39
146	The year in cardiology 2018: heart failure. <i>European Heart Journal</i> , 2019, 40, 651-661.	2.2	32
147	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 345-351.	7.1	43
148	Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial. <i>BMJ Open</i> , 2019, 9, e025525.	1.9	2
149	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	2.8	39
150	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1553-1560.	7.1	29
151	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 218-226.	7.1	25
152	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019, 40, 705-706.	2.2	1
153	Rapid right-sided deterioration in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2019, 40, 699-702.	2.2	4
154	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	3.3	10
155	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-HF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	7.1	68
156	Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. <i>Clinical Research in Cardiology</i> , 2019, 108, 612-621.	3.3	52
157	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	7.1	44
158	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019, 108, 477-486.	3.3	64
159	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 92-100.	1.2	48
160	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. <i>European Journal of Heart Failure</i> , 2018, 20, 910-919.	7.1	225
161	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
162	Value of digoxin in patients with heart failure: new pieces to the puzzle. <i>European Journal of Heart Failure</i> , 2018, 20, 1146-1147.	7.1	6

#	ARTICLE	IF	CITATIONS
163	Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study. <i>Scientific Reports</i> , 2018, 8, 5817.	3.3	1
164	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018, 138, 678-691.	1.6	229
165	Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. <i>European Heart Journal</i> , 2018, 39, 2987-2996.	2.2	203
166	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.	3.9	13
167	N-terminal pro-B-type natriuretic peptide and prognosis in <sc>Caucasian</sc> vs. <sc>Asian</sc> patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 279-287.	3.1	8
168	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2018, 11, e004519.	3.9	147
169	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	2.8	35
170	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	7.1	30
171	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	7.1	57
172	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	1.7	55
173	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	2.7	9
174	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.1	317
175	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	7.1	54
176	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 425-432.	1.2	93
177	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239
178	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	2.2	426
179	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2018, 121, 107-112.	1.6	22
180	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 621-627.	1.6	14

#	ARTICLE	IF	CITATIONS
181	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018, 24, 177-185.	1.7	65
182	Anemia in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 201-208.	4.1	65
183	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	2.9	16
184	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	2.1	6
185	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	1.7	140
186	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. <i>European Journal of Heart Failure</i> , 2018, 20, 1205-1214.	7.1	60
187	Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease. <i>International Journal of Cardiology</i> , 2018, 268, 106-112.	1.7	16
188	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	7.1	85
189	Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1559-1566.	7.1	173
190	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
191	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , 2018, 11, e004926.	3.9	26
192	Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. <i>Thrombosis Research</i> , 2018, 169, 123-127.	1.7	59
193	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. <i>Cardiovascular Research</i> , 2018, 114, 1871-1882.	3.8	38
194	Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018, 5, 1052-1059.	3.1	1
195	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	2.8	199
196	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.2	47
197	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	2.2	250
198	Atrial fibrillation is more troublesome in heart failure patients with preserved compared to those with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2018, 266, 155-156.	1.7	0

#	ARTICLE	IF	CITATIONS
199	Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	16
200	Role of Troponins I and T and <i>N</i> -Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. <i>Journal of Clinical Oncology</i> , 2017, 35, 878-884.	1.6	113
201	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	11
202	The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 862-869.	7.1	27
203	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	2.9	74
204	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	7.1	183
205	Plasma biomarkers to predict or rule out early postâ€“discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.1	34
206	Measuring Pulmonary Artery Pressures in Heart Failure. <i>Circulation</i> , 2017, 135, 1518-1521.	1.6	5
207	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). <i>Cardiovascular Pathology</i> , 2017, 29, 19-22.	1.6	3
208	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	1.7	42
209	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.	2.8	198
210	Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: nonâ€“identical twins?. <i>European Journal of Heart Failure</i> , 2017, 19, 880-882.	7.1	7
211	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	4.1	78
212	Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythmâ€“A CIBIS II analysis. <i>Clinical Cardiology</i> , 2017, 40, 740-745.	1.8	16
213	Vitamin D supplementation in heart failure: case closed?. <i>European Heart Journal</i> , 2017, 38, 2287-2289.	2.2	10
214	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 645-655.	1.8	12
215	Data Sharing From the Editors' Perspective. <i>JACC: Heart Failure</i> , 2017, 5, 314-315.	4.1	1
216	Predictors of left ventricular remodeling after ST-elevation myocardial infarction. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1415-1423.	1.5	20

#	ARTICLE	IF	CITATIONS
217	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. <i>Clinical Research in Cardiology</i> , 2017, 106, 598-609.	3.3	66
218	The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. <i>Clinical Cardiology</i> , 2017, 40, 322-328.	1.8	24
219	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	4.1	129
220	Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome. <i>International Journal of Cardiology</i> , 2017, 249, 145-150.	1.7	19
221	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017, 19, 1651-1660.	7.1	89
222	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1690-1697.	7.1	34
223	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	2.8	43
224	High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2017, 248, 51-56.	1.7	17
225	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO ₂ Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2017, 23, 777-782.	1.7	34
226	Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. <i>Clinical Research in Cardiology</i> , 2017, 106, 939-946.	3.3	22
227	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	36
228	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	7.1	53
229	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	4.1	238
230	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
231	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	2.6	8
232	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	7.1	34
233	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017, 19, 348-356.	7.1	38
234	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	1.7	30

#	ARTICLE	IF	CITATIONS
235	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017, 19, 116-125.	7.1	50
236	Rationale for and design of the <sc>TRUEâ€œAHF</sc> trial: the effects of ularitide on the shortâ€œterm clinical course and longâ€œterm mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	7.1	31
237	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	1.6	39
238	Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertensionâ€. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, 890-897.	1.1	42
239	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <sc>BIOSTATâ€œCHF</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	7.1	79
240	Signature of circulating <sc>microRNAs</sc> in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	7.1	162
241	Optimizing clinical use of biomarkers in highâ€œrisk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	7.1	69
242	Ischaemia in heart failure with preserved ejection fraction; is it important?. <i>European Journal of Heart Failure</i> , 2016, 18, 577-578.	7.1	5
243	Cardiac adaption during pregnancy in women with congenital heart disease and healthy women. <i>Heart</i> , 2016, 102, 1302-1308.	2.9	27
244	Serial galectin-3 and future cardiovascular disease in the general population. <i>Heart</i> , 2016, 102, 1134-1141.	2.9	42
245	Vagus Nerve Stimulation for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 149-158.	2.8	283
246	Right Ventricular Function After Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the Glycometabolic Intervention as Adjunct to Primary Percutaneous) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 <i>Cardiology</i> , 2016, 118, 338-344.	1.6	28
247	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	1.7	53
248	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	1.7	11
249	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1072-1081.	7.1	44
250	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	80
251	Plasma kidney injury moleculeâ€œ1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	7.1	32
252	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and metaâ€œanalysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1472-1487.	7.1	200

#	ARTICLE	IF	CITATIONS
253	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1420-1431.	2.8	85
254	52 Genetic Loci Influencing Myocardial Mass. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1435-1448.	2.8	113
255	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2217-2228.	2.8	292
256	Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. <i>Nature Genetics</i> , 2016, 48, 1557-1563.	21.4	131
257	Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ</i> , The, 2016, 353, i1855.	6.0	95
258	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. <i>European Journal of Heart Failure</i> , 2016, 18, 814-821.	7.1	13
259	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	7.1	149
260	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. <i>Human Molecular Genetics</i> , 2016, 25, 2093-2103.	2.9	24
261	Chronic ischemic mitral regurgitation and papillary muscle infarction detected by late gadolinium-enhanced cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction. <i>Clinical Research in Cardiology</i> , 2016, 105, 981-991.	3.3	17
262	Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. <i>European Heart Journal</i> , 2016, 37, 1681-1683.	2.2	11
263	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1527-1538.	1.8	3
264	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	35
265	Angiotensin II Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
266	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. <i>Clinica Chimica Acta</i> , 2016, 452, 50-57.	1.1	33
267	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	1.7	34
268	Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. <i>European Heart Journal</i> , 2016, 37, 2577-2585.	2.2	82
269	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.7	35
270	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	3.3	32

#	ARTICLE	IF	CITATIONS
271	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2016, 105, 10-16.	3.3	17
272	Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. <i>PLoS ONE</i> , 2016, 11, e0145719.	2.5	13
273	The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2016, 11, e0168340.	2.5	12
274	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.	7.1	35
275	Biomarkers and low risk in heart failure. Data from <scp>COACH</scp> and <scp>TRIUMPH</scp>. <i>European Journal of Heart Failure</i> , 2015, 17, 1271-1282.	7.1	55
276	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. <i>PLoS ONE</i> , 2015, 10, e0125215.	2.5	38
277	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> <i>Heart Journal</i> , 2015, 169, 693-701.e3.	2.7	16
278	The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000090.	2.8	23
279	Cardiac function and cardiac events 1-year postpartum in women with congenital heart disease. <i>American Heart Journal</i> , 2015, 169, 298-304.	2.7	27
280	Pulmonary Valve Replacement: Twenty-Six Years of Experience With Mechanical Valvar Prostheses. <i>Annals of Thoracic Surgery</i> , 2015, 99, 905-910.	1.3	33
281	Iron deficiency and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 659-669.	13.7	220
282	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.	2.2	30
283	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 2565-2573.	2.2	274
284	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <scp>COMMANDER HF</scp> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 735-742.	7.1	73
285	Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. <i>Clinical Research in Cardiology</i> , 2015, 104, 812-821.	3.3	6
286	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. <i>Nature Genetics</i> , 2015, 47, 1282-1293.	21.4	294
287	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 848-855.	1.7	17
288	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	2.7	18

#	ARTICLE	IF	CITATIONS
289	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.2	902
290	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	2.9	26
291	The <i>European Journal of Heart Failure</i> from 2010 to 2015. <i>European Journal of Heart Failure</i> , 2014, 16, 1259-1262.	7.1	1
292	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. <i>Europace</i> , 2014, 16, 1417-1425.	1.7	29
293	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2165-2173.	2.2	159
294	Rationale and design of the CONFIRM-CHF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	3.1	38
295	Genetic Determinants of P Wave Duration and PR Segment. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 475-481.	5.1	45
296	The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the Controlled ROSuvastatin multiNAtional trial in heart failure (CORONA). <i>BMC Medical Genetics</i> , 2014, 15, 140.	2.1	9
297	Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1526.	7.4	136
298	Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. <i>Heart</i> , 2014, 100, 1373-1381.	2.9	206
299	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	2.2	276
300	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 457-462.	3.9	60
301	Thirst Trajectory and Factors Associated With Persistent Thirst in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 689-695.	1.7	24
302	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) <i>Tj ETQq0 0 0 rgBT₁/Overlock₁₀ Tf 50 2</i>	1.6	61
303	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. <i>Circulation: Heart Failure</i> , 2014, 7, 723-731.	3.9	74
304	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1823-1832.	2.8	88
305	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. <i>Nature Genetics</i> , 2014, 46, 826-836.	21.4	281
306	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. <i>American Heart Journal</i> , 2014, 167, 853-860.e4.	2.7	128

#	ARTICLE	IF	CITATIONS
307	Effect of Right Ventricular Outflow Tract Obstruction on Right Ventricular Volumes and Exercise Capacity in Patients With Repaired Tetralogy of Fallot. <i>American Journal of Cardiology</i> , 2014, 113, 719-723.	1.6	23
308	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	1.7	147
309	The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	7.1	59
310	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. <i>Heart Rhythm</i> , 2014, 11, 1543-1550.	0.7	62
311	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. <i>American Heart Journal</i> , 2014, 168, 354-362.e2.	2.7	5
312	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	1
313	Iron deficiency in chronic heart failure: An international pooled analysis. <i>American Heart Journal</i> , 2013, 165, 575-582.e3.	2.7	532
314	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 417-424.	4.1	87
315	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 164-169.	4.1	40
316	Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 21-28.	4.1	123
317	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1498-1506.	2.8	352
318	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVENT. <i>European Heart Journal</i> , 2013, 34, 1424-1431.	2.2	451
319	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. <i>European Journal of Heart Failure</i> , 2013, 15, 1311-1318.	7.1	88
320	Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 525-525.	1.6	0
321	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011, 8, 485-493.	13.7	175
322	Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure. <i>Circulation</i> , 2011, 124, 1719-1726.	1.6	392
323	Telomere length and outcome in heart failure. <i>Annals of Medicine</i> , 2010, 42, 36-44.	3.8	37
324	Response to Letter Regarding Article, "Endogenous Erythropoietin and Outcome in Heart Failure". <i>Circulation</i> , 2010, 122, .	1.6	0

#	ARTICLE	IF	CITATIONS
325	Letter from the incoming Editor-in-Chief of the <i>European Journal of Heart Failure</i>. <i>European Journal of Heart Failure</i> , 2010, 12, 1-2.	7.1	8
326	The cardiopulmonary continuum systemic inflammation as â€˜common soilâ€™ of heart and lung disease. <i>International Journal of Cardiology</i> , 2010, 145, 172-176.	1.7	58
327	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) Tj ETQq1 1 0.784314 rgBT /Overlo of <i>Heart Failure</i> , 2009, 11, 1143-1151.	7.1	118
328	Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 582-588.	2.8	796
329	Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2150-2158.	2.8	405
330	1325 Severity of depressive symptoms is related to hospital admission in patients with heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2008, 7, 15-16.	0.9	0
331	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>European Heart Journal</i> , 2007, 28, 2208-2216.	2.2	184
332	1370: The impact of depressive symptoms and quality of life in HF patients compared with community dwelling elderly. <i>European Journal of Cardiovascular Nursing</i> , 2007, 6, 40-40.	0.9	0
333	Prescription of betaâ€‘blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. <i>European Journal of Heart Failure</i> , 2007, 9, 962-963.	7.1	1
334	Presence and development of atrial fibrillation in chronic heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 539-546.	7.1	91
335	Response to Letter Regarding Article, â€œRenal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failureâ€‘. <i>Circulation</i> , 2006, 114, .	1.6	1
336	Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardioversion (RACE) study. <i>American Heart Journal</i> , 2005, 149, 1106-1111.	2.7	177
337	Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. <i>Circulation</i> , 2002, 106, 1777-1782.	1.6	1,395
338	Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 139-145.	2.6	10
339	Ischemia and Left Ventricular Dysfunction: A Reciprocal Relation?. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, S46-S51.	1.9	14
340	Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials. <i>Cardiovascular Drugs and Therapy</i> , 1997, 11, 427-434.	2.6	12
341	Double-Blind Placebo-Controlled Study of Ibopamine and Digoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT). <i>Journal of the American College of Cardiology</i> , 1993, 22, 1564-1573.	2.8	158